

Head and Neck Cancer Pathways

Patient Name: _____ Date of Birth: _____

Member Number: _____ Treatment Start Date: _____

ICD-10 Code: _____ Pathology: _____

Stage: __0 __I __II __III __IVA __IVB __IVC __Recurrent

Line of Treatment: __Neoadjuvant/Pre-Op __ Adjuvant/Post-Op __First Line __Second Line __Second Line+

ECOG Performance Status: __ 0__ 1 __2 __3 __4

Hypopharynx and larynx: candidate for local therapy (M0) | Primary systemic therapy & concurrent radiation therapy (RT)

High dose cisplatin (Platinol) * with concurrent radiation therapy (RT)

Hypopharynx and larynx: candidate for local therapy (M0) | Post-operative systemic therapy & concurrent radiation therapy (RT)

High dose cisplatin (Platinol)* with concurrent radiation therapy (RT)

Lip, oral cavity, oropharynx, ethmoid sinus, maxillary sinus, occult primary: candidate for local therapy (M0) | Primary systemic therapy & concurrent radiation therapy (RT)

High dose cisplatin (Platinol)* with concurrent radiation therapy (RT)

Lip, oral cavity, oropharynx, ethmoid sinus, maxillary sinus, occult primary : candidate for local therapy (M0) | Post-operative systemic therapy & concurrent radiation therapy (RT)

High dose cisplatin (Platinol)* with concurrent radiation therapy (RT)

Nasopharynx: candidate for local therapy (M0) | Primary systemic therapy & concurrent radiation therapy (RT) followed by adjuvant therapy

High dose cisplatin (Platinol)* with concurrent radiation therapy (RT), followed by adjuvant cisplatin (Platinol) and fluorouracil (5FU)

Nasopharynx | Metastatic and recurrent disease | First and subsequent lines of therapy (1st line+) | Performance Status 0, 1, 2

Carboplatin (Paraplatin)

Cisplatin (Platinol)

Cisplatin (Platinol)** and gemcitabine (Gemzar)

Cisplatin (Platinol)** and paclitaxel (Taxol)

Fluorouracil (5FU)

Gemcitabine (Gemzar)

Gemcitabine (Gemzar) and vinorelbine (Navelbine)

Methotrexate

Paclitaxel (Taxol)

*High dose cisplatin is defined as dosing to achieve 200-300 mg/m² total cisplatin dose during the course of radiotherapy

**Substitution of carboplatin for cisplatin, and vice-versa, is acceptable for metastatic disease

Note: Pathway lists are solely for the purpose of eligibility for enhanced reimbursement and are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered.



Head and Neck Cancer Pathways

(Continued)

Non-Nasopharyngeal (Squamous cell) | Metastatic and recurrent disease | First line of therapy (1st line) | Performance Status 0, 1, 2

- __ Carboplatin (Paraplatin), fluorouracil (5FU), and cetuximab (Erbix)
- __ Cisplatin (Platinol), fluorouracil (5FU), and cetuximab (Erbix)

Non-nasopharyngeal (Squamous cell) | Metastatic and recurrent disease | Second and subsequent lines of therapy (2nd line +) | Performance Status 0, 1, 2

- __ Nivolumab (Opdivo)
- __ Paclitaxel (Taxol)

*High dose cisplatin is defined as dosing to achieve 200-300 mg/m² total cisplatin dose during the course of radiotherapy

**Substitution of carboplatin for cisplatin, and vice-versa, is acceptable for metastatic disease

Note: Pathway lists are solely for the purpose of eligibility for enhanced reimbursement and are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered.

